Business Wire

PHC Receives First EU-MDR Certification, Delivers Motorized Drug Injection Device Enabling More Efficient Patient-Friendly Treatment of Arthritis and Other Inflammatory Conditions

Share

The In Vitro Diagnostics Division of PHC Corporation (hereafter, PHC IVD), a provider of medical devices and diagnostics, today announced that it has received European Union Medical Devices Regulation (EU-MDR) certification for a motorized drug injection device that delivers anti-inflammatory medications called tumor-necrosis factor (TNF) inhibitors. The device, called APP-1000*1, is designed to provide simple, precise, and monitored drug injections in the home setting for conditions including rheumatoid arthritis. The EU-MDR certification clears the way for future distribution of the device in approximately 20 countries including EU countries, Switzerland, and South America.

APP-1000 is a class IIa*2 portable medical device, manufactured at PHC IVD’s Wakimachi plant in Japan. It allows patients to self-inject TNF inhibitors automatically at a touch of a button with no measurement or preparation required. The device comes equipped with an LCD screen with illustrated guidance to make it easier for patients to use. Dosing history stored in the device memory can be transferred via Bluetooth®*3 to a smartphone, allowing patients and doctors to check the dosing record remotely at any time. In addition, patients can choose from three injection speeds depending on their needs.

EU-MDR is a regulation for medical devices applied by the European Commission effective as of May 26, 2021. It replaces the Medical Devices Directive (MDD) and the Active Implantable Medical Devices Directive (AIMD), and establishes rules to improve the safety and quality of medical devices and provide transparency for patients to protect public health and patient safety. TÜV SÜD Product Service GmbH, an independent third-party certification organization (or “Notified Body”) based in Germany, conducted the technical documentation reviews and audits required for APP-1000 to be certified. It is PHC Corporation’s first device to receive the EU-MDR certification.

Hiroyuki Tokunaga, Member of the Board of PHC Corporation and Director of PHC IVD said, “We strive to provide best-in-class healthcare solutions that meet the needs of healthcare professionals and improve patients’ quality of life, by integrating precision manufacturing with digital technology. This EU-MDR certification will enable APP-1000 to be available to more patients and is an important milestone in our work to improve healthcare in the field of digital injectors.”

This device is currently available in Japan. With the EU-MDR certification, PHC IVD plans to make it available in EU countries, Switzerland, and South America after June 2022.

*1 www.phchd.com/global/ivd/digital-injector
*2 EU-MDR classifies medical devices into four categories, taking into account the intended purpose of the devices and their inherent risks; Class I (lowest-risk), Class IIa, Class IIb, and Class III (highest-risk).
For further information on classification of medical devices: ec.europa.eu/health/system/files/2021-10/mdcg_2021-24_en_0.pdf
*3 The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by PHC Corporation is under license. Other trademarks and trade names are those of their respective owners.

About In Vitro Diagnostics (IVD) Division, PHC Corporation

Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO 6523), a global healthcare company that develops, manufactures, sells and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. With the mission to contribute to the health of society through healthcare solutions that have a positive impact and improve the lives of people, its IVD Division has worked to improve medical services for patients by contributing to early diagnosis and effective medical care for diseases such as diabetes and asthma through development, manufacturing, and distribution of testing and analyzing devices including blood glucose monitoring systems.
www.phchd.com/global/ivd

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Hiroko Arai
Investor Relations & Corporate Communications Department
PHC Holdings Corporation
+81-3-6778-5311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RMS Launches New Cloud-Based Application UnderwriteIQ17.5.2022 17:47:00 EEST | Press release

RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, announces it will be launching a new application, UnderwriteIQ™, hosted on the cloud-based RMS Intelligent Risk Platform™. UnderwriteIQ enables underwriters to have greater control of risks by bringing hazard, exposure, and loss data together in the underwriting process at the point of decision – all based on RMS model science and data. The new application will allow underwriters to price with confidence, enable consistent risk decisions, and improve operational efficiency. The application is hosted on the modular and unified RMS Intelligent Risk Platform (IRP). The platform provides proprietary and tertiary data analytics to rapidly generate high-resolution risk insights via applications that meet underwriting and portfolio management needs. Moe Khosravy, Executive Vice President, Software and Platform, RMS, said: “The growth in adoption of the RMS Intelligent Risk Platform has been phenomenal. A

GC Aesthetics® Announces the Launch of FixNip™: a Total Game-Changer in Breast Reconstruction17.5.2022 17:15:00 EEST | Press release

GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Healthcare Aesthetic Solutions, announced the launch of an Innovative Nipple Areola Complex (NAC) Reconstruction Implant : FixNip™ NRI. This unrivalled medical device is the answer to a well-known clinical need of thousands of women around the world. Until now, a variety of surgical techniques are used to try to reconstruct the nipple areola complex with none providing a long term aesthetic solution. GC Aesthetics® in an exclusive partnership agreement with FixNip LTD is proud of launching FixNip NRI in main European Territories, while the roll-out to Latin America, Central Europe and Asia will be announced later this year. "We are committed to deliver safe options that establish a newer, higher, and more beneficial standard of care for women who seek to total breast reconstruction. Such technology breakthrough will complete our range of solutions dedicated to women aesthetic healthcare. FixNip by GC Aest

Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse17.5.2022 17:00:00 EEST | Press release

Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital, an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/ LDA Capital lands on Enry's Island, with a € 20M round (Graphic: Business Wire) “We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster

Regulatory Framework for E-cigarettes Essential in Moroccan and Algerian Markets as Prevalence of Smoking Expected to Rise Notably By 202517.5.2022 16:26:00 EEST | Press release

RELX International, a responsible multinational electronic cigarettes company, is urging decision-makers in Morocco and Algeria to roll out comprehensive regulatory frameworks for e-cigarettes, ahead of an expected surge in smoking habits. Longstanding research has shown that smoking traditional, tobacco-based cigarettes poses significant health risks. According to data compiled by website GSTHR.org (Global State of Tobacco Harm Reduction), there has been an upward trend in current smoking prevalence in the general population in Morocco. In 2015, overall prevalence was estimated to be 23%, with a projection to increase to 28% by 2025 in Morocco. [1]. While in Algeria, current smoking trends for the overall adult population is also projected to increase, with an estimate of 16.9% by 2025 as per GSTHR.org. [2]. In contrast to traditional cigarettes, e-cigarettes are increasingly being hailed as a better alternative and can even help adult smokers reduce or quit smoking entirely according

Oregon Tool Celebrates 75th Anniversary17.5.2022 16:22:00 EEST | Press release

In 1947, forester Joe Cox observed the C-shaped jaws of a timber beetle larva deftly chewing through wood. This was the inspiration for his “Cox Chipper Chain,” which he quietly invented in the basement of his home in Portland, Oregon. That same year, Cox started the Oregon Saw Chain Corp. to produce his saw chain – from a basement startup to a global manufacturer. Over time, Cox and his saw chain revolutionized the timber industry, and today the company he founded is the manufacturer of the World’s #1 Saw Chain™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005669/en/ Oregon Tool 75th Anniversary: Seeding the Roots of Our Future. (Graphic: Business Wire) The company – known today as Oregon Tool – has grown into a multinational organization with numerous acquisitions and mergers. At 3,000 Team Members strong, Oregon Tool sells thousands of products in more than 110 countries. Oregon Tool is a top manufacturer of saw

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom